19 / 40
AFLAC JAPAN PRODUCTS
FIRST SECTOR PRODUCTS
THIRD SECTOR PRODUCTS
Life
• Term
• Whole
• Hybrid (WAYS)
Child Endowment
Fixed Annuity
Cancer
Medical
Aflac has been selling first sector life products with smaller
face amounts since 1996. Starting in December 2007, banks
were permitted to sell the traditional health-related products
that Aflac offers to its customers, and the bank channel
quickly became a larger contributor to sales.
WAYS
In 2006, WAYS was introduced, and banks started selling
this unique hybrid whole-life product in 2008. WAYS can
be converted to a fixed annuity, medical coverage or
nursing care benefits when the policyholder reaches a
predetermined age.
Child Endowment
In 2009, Aflac introduced a competitive child endowment
product that pays a lump-sum benefit at the time of a child’s
entry into high school and an educational annuity for each of
the four years of college.
Fixed Annuity
In 1999, Aflac introduced a fixed annuity product to enhance
our product portfolio.
The foundation of our product portfolio has been, and
continues to be, supplemental health products, like cancer
and medical insurance.
Cancer Insurance
In 1974, Aflac pioneered the cancer product in Japan, and we
remain the number one provider of cancer insurance today.
As part of our continual efforts to ensure we’re responding to
customer and distribution needs, we introduced New Cancer
DAYS in September 2014.
Medical Insurance
In early 2002, we first introduced EVER, a stand-alone,
whole-life medical product, as a solution to help Japanese
citizens with rising copayments related to Japan’s universal
health care coverage. Within one year of the introduction of
EVER, Aflac became the leading seller of medical insurance
in Japan.
To ensure we remain in step with the wants and needs of Japanese consumers
and our distribution channels, Aflac Japan continually enhances its portfolio of
products. In September 2014, we introduced New Cancer DAYS, the latest revision
to our cancer product offering, which also includes an exclusive product sold through
Japan Post. Sales of cancer insurance surged following this product introduction,
with sales through all distribution outlets up a tremendous 176% for the fourth quarter
and 36.6% for the year, solidifying our position as the number one provider of cancer
insurance. This dramatic increase in cancer insurance sales was critical to Aflac
Japan nearing the high end of our 2% to 7% annual sales target.
AFLAC JAPAN
17